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Abstract 
Background. Individuals genetically susceptible to malignant hyperthermia (MH) 
exhibit hypermetabolic reactions when exposed to volatile anaesthetics. Mitochondrial 
dysfunction has previously been associated with the MH-susceptible (MHS) 
phenotype in animal models but evidence of this in human MH is limited.  
Methods. We used high resolution respirometry to compare oxygen consumption 
rates (oxygen flux) between permeabilized human MHS and MH-negative (MHN) 
skeletal muscle fibres with or without prior exposure to halothane. A substrate-
uncoupler-inhibitor titration protocol was used to measure the following components 
of the electron transport chain under conditions of oxidative phosphorylation 
(OXPHOS) or after uncoupling the electron transport system (ETS): complex I (CI), 
complex II (CII), complex I and II together (CI+CII) and, as a measure of 
mitochondrial mass, complex IV (CIV). 
Results. Baseline comparisons without halothane exposure showed significantly 
increased mitochondrial mass (CIV, p=0.021) but lower flux control ratios (FCR) in 
CI+CII(OXPHOS) and CII(ETS) of MHS mitochondria compared to MHN (p=0.033 and 
0.005 respectively) showing that human MHS mitochondria have a functional 
deficiency. Exposure to halothane triggered a hypermetabolic response in MHS 
mitochondria significantly increasing mass-specific oxygen flux in CI(OXPHOS), 
CI+CII(OXPHOS), CI+CII(ETS) and CII(ETS) (p= 0.001 ± 0.012), while the rates in MHN 
samples were unaltered by halothane exposure.  
Conclusion. We present evidence of mitochondrial dysfunction in human MHS 
skeletal muscle both at baseline and after halothane exposure.  
 
Keywords: Malignant hyperthermia; skeletal muscle; mitochondria; electron 
transport chain 
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Malignant hyperthermia (MH) is a hypermetabolic reaction triggered by potent 
inhalation anaesthetics in susceptible individuals 1. Direct consequences of the 
hypermetabolic state are increased carbon dioxide production, increased oxygen 
consumption, metabolic acidosis, and hyperthermia, with reflex sympathetic 
stimulation 2. Ultimately skeletal muscle ATP production fails to keep up with energy 
requirements leading to muscle rigidity and rhabdomyolysis 2. Variants in the RYR1 
gene that encodes the skeletal muscle calcium release channel (ryanodine receptor, 
RyR1 3) or the CACNA1S gene that encodes the sarcolemmal slow voltage gated Ca2+ 
channel which acts as the voltage sensor for excitation-contraction (EC) coupling 
(dihydropyridine receptor, DHPR 4, 5) are associated with MH in 76% of UK MH 
families 6. Both proteins work in concert to regulate Ca2+ levels in skeletal muscle at 
rest and during EC coupling 7. Prior to the discovery of genetic linkage between RYR1 
and MH-susceptibility 8, 9, several researchers postulated an important role for 
mitochondria in the development of an MH reaction. Recent findings in transgenic 
mice with RYR1 mutation knock-in has rekindled interest in such a role for 
mitochondria 10-12. There is also the implication that mitochondrial dysfunction may 
explain why some MH susceptible individuals experience myopathic traits such as 
muscle weakness and exercise intolerance 13.  
Some of the earliest observations in MH mitochondria were conducted on the MH 
porcine model, which showed a halothane-induced inhibition of complex I 14, 15 . 
Research on RYR1 mutation knock-in mouse models has found mitochondrial 
abnormalities with various degrees of severity depending on the RyR1 mutation. 
Notable observations have included lower oxidative phosphorylation (OXPHOS), 
increased oxidative stress and increased reactive oxygen species (ROS) production 10-
12. On a structural level, mitochondrial deformity - an indication of damage - has been 
observed in multiple reports using electron microscopy. These reports often denote a 
loss of cristae organization and mitochondrial swelling which suggests there may be 
metabolic dysfunction and altered OXPHOS in muscles from both MH susceptible 
mice 10, 16 and humans 17, 18.  
In contrast to animal models, research on human MH mitochondrial function is 
lacking. Despite the structural abnormalities seen in MH susceptible humans 17, 18, 
evidence for the existence of functional defects is conflicting. Some reports suggest 
normal OXPHOS and respiratory control in mitochondria of MH susceptible humans 
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19, whilst others have claimed impaired OXPHOS and ATP production after bouts of 
training in MH susceptible individuals 20. The discrepancies may be explained by 
variation in sample type, methodology or both. The purpose of this study was to 
investigate whether mitochondrial dysfunction is present in ex vivo skeletal muscle 
from MH susceptible humans under 1) basal conditions and 2) after halothane 
exposure. 
 
Methods 
Patients 
Patients who were considered for inclusion in this study were those attending for 
investigation of their susceptibility to MH. The reason for investigation was a clinical 
suspicion of increased risk either because they had had an adverse reaction to 
anaesthesia consistent with MH or because a family member was known to be MH 
susceptible. The majority of index case patients had been found not to harbour a 
pathogenic variant (www.emhg.org) in RYR1 and CACNA1S prior to attending for 
further investigation, which involved an open muscle biopsy and subsequent in vitro 
contracture testing (IVCT). Family members were either from families where no 
pathogenic variant had been found or who had been found not to carry a familial 
variant. Patients gave written informed consent to the study that was approved by 
Leeds (East) Research Ethics Committee (reference 10/H1306/70). 
Patients were diagnosed using the IVCT as either MH susceptible (MHS) or MH 
negative (MHN) according to the protocol of the European MH Group 21. The 
laboratory classification of MHS is subdivided into MHShc (samples respond 
abnormally to both caffeine and halothane challenges), MHSh (samples respond 
normally to caffeine but abnormally to halothane challenge) or MHSc (samples 
respond abnormally to caffeine but normally to halothane challenge). 
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Muscle samples 
Diagnostic muscle biopsies and IVCTs were conducted according to the protocol of the 
European MH Group 21. In brief, six muscle fascicles (typical dimensions 25 mm x 4 
mm x 3mm) were excised from Vastus medialis under femoral nerve block and 
immediately SODFHGLQR[\JHQDWHG.UHEV¶VROXWLRQP01D&OP0.&O
mM MgSO4, 1.2 mM KH2PO4, 11.1 mM Glucose, 25.0 mM NaHCO3, 2.5 mM CaCl2, pH 
7.4) at room temperature and taken to the MH laboratory. There, the samples were 
NHSWDWURRPWHPSHUDWXUHLQWKH.UHEV¶VROXWLRQ, which was gassed continuously with 
carbogen (95% O2, 5% CO2), until being used for the IVCT tests. This study required 
both a muscle fascicle that had not been used for the diagnostic challenge tests 
(baseline) and a fascicle that had been used in the static halothane test (halothane-
exposed). At the end of the halothane test procedure both the halothane-exposed and 
baseline samples were each placed into 1 ml of ice-cold biopsy preservation buffer, 
BIOPS (2.77 mM CaK2EGTA, 7.23 mM K2EGTA, 5.77 mM Na2ATP, 6.56 mM 
MgCl2·6H2O, 20 mM taurine, 15 mM Na2Phosphocreatine, 20 mM imidazole, 0.5 mM 
dithiothreitol (DTT), and 50 mM MES hydrate, pH 7.1, adjusted with 5 N KOH at 0 
°C). The samples were then placed in a petri dish with ice cold BIOPS and separated 
using sharp forceps to obtain small muscle fibre bundles containing approximately 4-
5 fibres each. These samples then underwent chemical permeabilization in BIOPS 
containing VDSRQLQǋJāPO-1) for 30 min, before being washed with 1 ml respiration 
medium, Mir05 (0.5 mM EGTA, 3 mM MgCl2·6H2O, 60 mM lactobionic acid, 20 mM 
taurine, 10 mM KH2PO4, 20 mM HEPES adjusted to pH 7.1 with KOH at 37 °C, 110 
mM D-sucrose, and 1 g·L-1 essentially fatty acid free BSA) to remove residual saponin. 
The sample was then taken out of solution and blot-dried for 5 s before being weighed 
and loaded into the respirometer chambers (5-10 mg in each chamber) containing 2 
ml of Mir05. The time between biopsy collection and assay time was approximately 90 
± 120 min. This sample preparation procedure was adapted from previously described 
protocols 22, 23. 
 
High Resolution Respirometry  
Oxygen consumption over time was measured using Oroboros respiratory analysers 
(Oroboros Instruments, Innsbruk, Austria) at 2 s intervals with polarographic oxygen 
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sensors and expressed as mass-specific oxygen flux (pmol/s*mg). The analyser was 
calibrated daily in air saturated solution before experimentation. Assays were initiated 
by injecting oxygen into each chamber to raise the oxygen concentration to > 400 
nmol/mL prior to starting a substrate-uncoupler-inhibitor titration (SUIT) protocol. 
Re-oxygenation of the chambers was performed to maintain oxygen concentration 
between 200-500 nmol/mL to prevent limitation due to oxygen diffusion 23. Each 
assay was performed at 37 °C, with chamber stirrers set at 750 rpm.  
 
SUIT protocol 
An adapted SUIT protocol was used to investigate the OXPHOS capacity of individual 
complexes and respiratory states 22, 23 and is summarised in Figure 1. The procedure 
was initiated with the addition of 5 ǋ0blebbistatin (BLEB) to prevent spontaneous 
contraction of muscle fibres 24. Glutamate (10 mM), malate (0.5 mM) and pyruvate (5 
mM) were then applied to facilitate measurements of the complex I respiration in the 
absence of ADP (LEAK). ADP (2.5 mM) is then added next to allow the measurement 
of maximal complex I-supported OXPHOS (CI(OXPHOS)). At this point the outer 
mitochondrial membrane integrity was assessed E\WKHDGGLWLRQRIǋ0cytochrome 
c. An increased respiration rate after addition of cytochrome c indicates outer 
mitochondrial membrane damage: samples that showed an increased respiration rate 
after cytochrome c of >10% were excluded from data analysis. 
Once membrane integrity has been assessed, the maximal activity of complex II is 
stimulated with the addition of succinate (10 mM). The oxygen flux at this stage 
(CI+CII(OXPHOS)) reflects the combined activities of complex I and complex II together 
and is also regarded as the maximum OXPHOS capacity in the coupled state. Next, 
step-wise additions of carbonyl cyanide 4-(trifluoromethoxy)-phenylhydrazone 
)&&3ǋ0) are made until there is no further increase in oxygen flux. This step-
wise addition of FCCP uncouples the electron transport system (ETS) by collapsing the 
proton gradient between the intermembrane space and the mitochondrial matrix 
providing the maximum ETS capacity (CI+CII(ETS)). Then, after uncoupling the 
system, electron flow through complex I is inhibited using rotenone ( ǋ0
providing maximum complex II activity alone (CII(ETS)). Finally, antimycin A is 
introduced to inhibit complex III. Complex III activity is technically contributing to all 
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data points aside from the Complex IV assay. However, its activity is not measured 
directly in this protocol as it obtains electrons downstream of complex I and II. 
Residual oxygen flux (ROX) present after the addition of antimycin A is a result of non-
mitochondrial respiration which is then subtracted from each respiratory state reading 
before analysis. 
 
Complex IV Assay 
Measurement of mass-specific complex IV oxygen flux was used as an alternative 
proxy marker for estimations of mitochondrial content. Ascorbate (2 mM) and 
111Ļ1Ļ-tetramethyl-p-phenylenediamine (TMPD) (0.5 mM) was applied to each 
sample at the end of the standard SUIT protocol. The measurement of complex IV flux 
is taken at the peak of the corresponding trace and residual chemical background is 
finally removed from this value by applying sodium azide (10 mM) to the sample 25. 
 
Data handling and analysis 
Raw data output is in the form of oxygen flux per muscle mass (pmol/s*mg) which 
includes the confounding effects of both mitochondrial quality and quantity. The data 
in this study, from samples with and without halothane exposure, were internally 
normalised to the common reference state, CI+CII(ETS) (maximum uncoupled 
respiration). Normalised oxygen flux per mass is presented as flux control ratios (FCR) 
which highlight differences in mitochondrial function, as a proportion of the reference 
state, which is independent of mitochondrial content.  
Oxygen flux readings recorded from each sample trace were exported from proprietary 
software DatLab5 (Oroboros Instruments, Innsbruk, Austria) into Microsoft Excel 
before analysis using IBM SPSS statistics v21. Pairwise comparisons were performed 
using a combination of Wilcoxon signed-rank tests to assess the effects of halothane-
exposure and Mann-Whitney U tests to assess median differences between baseline 
controls. Further analysis using MHS subgroups involved a Kruskal-Wallis test and 
SRVWKRF'XQQ¶VSURFHGXUHto identify differences between patients classified as MHN, 
MHSh and MHShc. Data were summarised as boxplots using GraphPad Prism 8. There 
are no data on the magnitude of changes in OXPHOS variables that are associated with 
human pathology. Preliminary data from a transgenic mouse model of MH suggested 
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that there was a standardized mean difference of 0.86 in baseline CI+CII(ETS) between 
MHS and MHN mice. Such a difference would be detected with a sample size of 12 in 
each group with D < 0.05 and E < 0.2. We sought to identify changes with a 
standardized difference in means of >0.75 as this is generally accepted as a relevant 
effect size in biological systems. On the basis that the MH Unit records more people 
with MHN compared with MHS diagnoses, we planned to include samples from 23 
MHS and at least 35 MHN, in order to achieve D < 0.05 and E < 0.2. This number of 
samples enables detection of paired (with and without halothane exposure) 
standardized mean differences of 0.6 and 0.5 for MHS and MHN samples respectively. 
 
Results  
Patient characteristics 
A summary of patient characteristics is presented in Table 1. Eighteen of the 23 MHS 
group were subsequently found to carry at least one variant in the RYR1 gene and these 
variants are also listed in Table 1. None of the patients had clinical or histopathological 
features suggestive of a mitochondrial myopathy. We included 59 individuals from 52 
families: the maximum number from any family was 2 individuals. 
 
Mass-specific oxygen flux comparisons 
Oxygen flux per milligram of muscle was compared between MHN and MHS samples, 
with or without exposure to halothane (Fig 2). Comparisons of samples without 
halothane exposure showed no differences between the two phenotypes aside from 
CIV (MAX) where MHS samples had a significantly greater oxygen flux when compared 
to MHN (p=0.021), suggesting higher mitochondrial content in the MHS samples. 
Pairwise comparisons showed that oxygen flux was significantly elevated in MHS 
samples after halothane exposure in several respiratory states: CI(OXPHOS), 
CI+CII(OXPHOS), CI+CII(ETS) and CII(ETS) (Table 2). The rates in MHN samples were 
unaltered by halothane exposure.  
 
Flux control ratios (normalised oxygen flux) 
9 
 
Mass-specific oxygen flux was normalised to a common reference state (control 
CI+CII(ETS)) to generate FCR which removes the confounding effects of mitochondrial 
content differences among samples (Fig 3). Comparisons of FCR at baseline revealed 
that CI+CII(OXPHOS) and CII(ETS) were significantly lower in MHS samples when 
compared to MHN (p=0.033 and 0.005, respectively, Table 2), suggesting functional 
deficiency. Normalised CIV(MAX) showed no significant differences between MHS and 
MHN controls indicating similar functional capacity of complex IV. In addition, FCR 
comparisons between control and halothane-exposed samples support the findings 
seen in the mass-specific dataset, with statistically significant findings in several of the 
same respiratory states (Table 2). However, one exception was found in MHN CII(ETS) 
which increased after halothane-exposure (p=0.041).  
 
FCR responses within the subdivided MHS phenotypes 
FCR were used for further analysis within the MHS phenotype, comparing the 
magnitude of change with and without exposure to halothane between the MHSh and 
MHShc phenotypes - (Fig 4) ± there were no patients in this sample categorized as 
MHSc. Results from the Kruskal-Wallis test showed that CI+CII(OXPHOS) responses 
differed significantly between MH phenotypes after halothane exposure (Table 2). 
Post hoc analysis showed that these differences in response between MHN and MHS 
groups is largely attributable to responses of the MHShc subgroup because we did not 
find any significant differences in response to halothane exposure between the MHN 
group and the MHSh subgroup. 
 
Discussion 
Baseline comparisons using mass-specific flux showed a significantly higher CIV(MAX) 
in MHS compared with MHN muscle, which indicates a greater mass of mitochondria 
in MHS muscle per milligram of tissue. Alternative mitochondrial markers such as 
citrate synthase and mtDNA were considered for this study but the complex IV assay 
was chosen as it can be performed during the experiment and allows measurements 
on the same exact sample, avoiding issues with degradation. To normalise for 
differences in mitochondrial mass we compared FCR data which showed that there 
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were functional deficits in MHS muscle as well. The CI+CII(OXPHOS) and CII(ETS) FCRs 
were significantly lower in MHS samples compared to MHN which implies that there 
is uncoupling of mitochondria in MHS muscle in addition to complex II deficiency, 
both of which would likely result in inefficient ATP production. The uncoupling of 
MHS mitochondria is perhaps a side effect of the swelling and structural abnormalities 
seen in previous human studies 18 or it may be a consequence of chronically elevated 
myoplasmic calcium concentration in MHS muscle (see below). Since no significant 
differences in CI(OXPHOS) were found, complex II deficiency seems to be the primary 
cause for the reduced maximum OXPHOS capacity of MHS muscle as defined by 
CI+CII(OXPHOS) FCR. This is of great importance as a lower OXPHOS capacity suggests 
that the ETS in MHS mitochondria is less tightly coupled and they are therefore less 
efficient than MHN mitochondria at producing ATP. Complex II, also known as 
succinate dehydrogenase, is the only component of the ETS which is encoded entirely 
by nuclear genes and has roles in both OXPHOS and the Krebs¶ cycle, indirectly 
affecting glycolysis 26. Complex II deficiency has not previously been linked to MH 
susceptibility and its deficiency may mean that the glycolytic function of MHS muscle 
is also impaired - a potential area for further research. Collectively these findings may 
also suggest a potential compensation mechanism, in which MHS muscle upregulates 
mitochondrial numbers to counteract deficiencies in mitochondrial function, hence 
similar baseline oxygen flux per unit of muscle mass.  
The proposed concept of mitochondrial deficiency in MHS muscle is consistent with 
that seen in other studies 11,15,20, but some findings are conflicting. An example is the 
work of Giulivi et al11, who found a decrease in mitochondrial content, reduced oxygen 
uptake using malate-glutamate and succinate, and complex I, III and IV deficiency in 
R163C knock-in mice when compared to wild-types. In contrast, our study showed 
evidence of human MHS muscle having higher mitochondrial content, deficiency in 
succinate-facilitated oxygen flux, with activity deficits in complex II only. These 
discrepancies may be a result of species differences but they could also be explained 
by differences in methodology. The study of Giulivi and colleagues used isolated 
mitochondria in the assessment of mitochondrial content and protein complex 
function, 11 whereas we used permeabilized muscle fibres. Permeabilized muscle allows 
interplay between the mitochondria, SR and RyR1, which we believe is crucial to 
accurately assess the biological effects of MH. Furthermore, the oxygen uptake assay 
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in the mouse study was conducted at  22 °C whereas we used a physiological 37 °C for 
our experiments: assay temperature significantly impacts OXPHOS capacity 27.  
 
As previously mentioned, one hypothesis for the mitochondrial dysfunction in MHS 
muscle observed here may be the result of chronic elevation in cytosolic Ca2+ that has 
been demonstrated in human 28 and porcine 29 MH muscle as well as knock-in mouse 
models 11,12,30. Ca2+ increases mitochondrial activity which can stimulate higher rates 
of ROS production through complex I, III and, as has been recently shown, complex II 
of the ETS 31. Increased ROS production has been observed in MH RYR1 knock-in mice 
11 and it is possible that this may translate into human MHS muscle. Increased ROS 
production, which can cause DNA damage and structural damage to organelles, could 
explain the mitochondrial swelling seen in previous electron microscopic studies 
10,16,18. Ca2+ is also a positive regulator of the mitochondrial permeability transition 
pore (MPTP) of the inner mitochondrial membrane 32. Opening of the MPTP decreases 
the proton gradient across the inner mitochondrial membrane which is associated 
with uncoupling of the ETS from OXPHOS 33. 
We have also shown that increased activity of several mitochondrial respiratory states 
is involved in the hypermetabolic response in MHS mitochondria following exposure 
to halothane. This could simply be a response driven by conversion of myoplasmic ATP 
to ADP but Diaz-Vegas and colleagues have recently demonstrated a more direct link 
between skeletal muscle mitochondrial stimulation and activation of RyR1 34. This may 
be the result of sarcoplasmic reticulum Ca2+ efflux from the activated RyR1 in MHS 
muscle and uptake by the mitochondria. Increased intramitochondrial Ca2+ stimulates 
dehydrogenase enzymes which in turn increase NADH and ATP production 35, 36. The 
rhabdomyolysis and cell death which occurs in a fulminant MH reaction may partly be 
caused by the failure of skeletal muscle mitochondria to maintain ATP production to 
accommodate the Ca2+ stimulated state along with apoptotic mechanisms activated by 
increased intramitochondrial Ca2+. The FCR of MHN CII(ETS) also increased after 
exposure to halothane, suggesting a non-RyR1 mediated component of this effect of 
halothane. However, the clinical relevance of this phenomenon is uncertain as it 
occurs in an artificially uncoupled non-physiological state. 
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A recent study of Canadian MH susceptible patients found that those who responded 
abnormally to halothane but not caffeine in the caffeine-halothane contracture test 
had a higher index of calcium related changes in cultured skeletal muscle cells than 
patients who responded abnormally to halothane and caffeine 37. We compared the 
magnitude of FCR changes in MHSh and MHShc fibres and found a significantly greater 
effect of halothane exposure on (CI+CII(OXPHOS)) in MHShc muscle, which is what we 
expected, although it is at odds with what might have been anticipated from the work 
of Figueroa and colleagues 37. This potential discrepancy might be explained by the use 
of cultured myotubes by Figueroa and colleagues whereas we studied adult muscle 
fibres. 
Another unexpected observation was the lack of change in CI(OXPHOS) after halothane 
treatment. Complex I activity was reduced by halothane in MH pigs 11, 12 but research 
in other models has suggested this effect is independent of the MH trait. Porcine heart 
mitochondria have shown reversible dose-dependent inhibition of complex I (NADH 
oxidoreductase) after exposure to isoflurane, sevoflurane and halothane ± the latter of 
which proved to be the most potent among them 38. Research using the complex I 
mutant gas-1 C.elegans model has also shown evidence of decreased complex I 
function and increased sensitivity to the application of potent inhalation anaesthetics 
39, 40. This was not observed in our MHS or MHN muscle and may be due to the 
inhibitory effects of halothane on complex I being both acute and reversible. Such 
changes would not be detected using our protocol because of the time delay between 
halothane exposure and measurement of mitochondrial function (~90 -120 min). In 
addition, previous studies with halothane treatment have used isolated mitochondria 
taken out of the normal cellular environment11,12.  
The time delay between halothane exposure and measurement of mitochondrial 
function might also have reduced the magnitude of change in other components of the 
ETS and could have obscured other acute and reversible changes. It is also possible 
that the permeabilization of the muscle fibres, which is necessary for the SUIT 
protocol, might have limited the responses to halothane exposure. A further potential 
confounding factor in our study was that the halothane-exposed samples were 
maintained at approximate physiological length and tension as well as being 
electrically stimulated during the halothane contracture test, whereas the baseline 
samples were not. While we think it may be that the differences observed between our 
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halothane-exposed and baseline samples are a result of the halothane exposure rather 
than the other interventions, we were unable to demonstrate this because of a limited 
supply of human muscle tissue. We plan to address this in future studies using muscle 
tissue from RYR1 knock-in mouse models. 
 
In conclusion, we have demonstrated evidence of impaired mitochondrial function in 
permeabilised human MHS skeletal muscle and we hypothesise that this results from 
chronic elevation of cytoplasmic Ca2+ in MHS muscle that causes mitochondrial 
uncoupling and structural damage through increased ROS production. Exposure to 
2% halothane significantly increased OXPHOS and ETS capacity in MHS muscle, 
confirming a hypermetabolic response to halothane in MHS mitochondria with 
functional deficiency at baseline.  
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Table 1 
 
Table 1. Summary of characteristics of the patients contributing samples for this study. MHN= malignant hyperthermia negative; 
MHS = malignant hyperthermia susceptible; MHSh = abnormal response in the in vitro contracture test to halothane but not caffeine; 
MHShc = abnormal response in the in vitro contracture test to halothane and caffeine. The RYR1 variants are annotated for their likely 
In vitro contracture 
test result 
MHN 
(n = 36) 
MHS (n = 23) 
MHSh (n = 12) MHShc (n = 11) 
Male: Female 16: 20 5: 7 7: 4 
Age at biopsy (years) (11 ± 68) (12 ± 64) (12 ± 57) 
Individuals with at least 
one RYR1 variant 
- 8 10 
RYR1 variants found 
 
- 
Nucleotide 
change 
Amino acid 
change 
Accession 
number 
Nucleotide 
change 
Amino acid 
change 
Accession 
number 
c.251C>Tb  p.Thr84Met rs186983396 c.455C>Ab p.Ala152Asp - 
c.4178A>Ga p.Lys1393Arg rs137933390 c.1202G>Ac p.Arg401His rs193922766 
c.5183C>Tc p.Ser1728Phe rs193922781 c.8729C>Tb p.Tyr2910Met - 
c.6670C>Tb  p.Arg2224Cys rs199870223 c.10357C>Tb p.Arg3453Cys rs1482429489 
c.6785G>Ab p.Gly2262Asp - c.11132C>Tc p.Thr3711Met rs375915752 
c.7879G>Ac p.Val2627Met - c.11958C>Gc p.Asp3986Glu rs193922842 
c.12860C>Tb p.Ala4287Val - c.12700G>Cc p.Val4234Leu rs193922852 
c.14210G>Ac p.Arg4737Gln rs193922868 c.7879G>A
c p.Val2627Met - 
c.4293G>A      p.Thr1431=  rs727504130 
c.1021G>Ad p.Gly341Arg rs121918592 
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pathogenicity using the criteria of Miller et al6 as: a. Unlikely pathogenic; b. Potentially pathogenic; c. Likely pathogenic; d. 
pathogenic. IVCT contracture data for each MHS individual is available in supplementary table 1.
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Table 2 
 
 
Table 2.  Summary of all statistical comparisons for each data set, outlining the 
specific p values for each pairwise comparison between and within phenotype for the 
mass-specific oxygen flux (pmol/s*mg) and FCR readings. The p values for FCR 
differences between MHS subgroups are also included with post hoc statistics for each 
comparison. MHN= malignant hyperthermia negative; MHS = malignant 
Respiratory 
State 
Oxygen consumption rate (pmol/s*mg) 
MHN MHS MHN vs MHS 
Control vs halothane-exposure    
(p value) 
Control comparisons (p 
value) 
LEAK    0.944 0.429 0.732 
CI(OXPHOS) 0.593 0.012 0.113 
CI+CII(OXPHOS)  0.789 0.005 0.071 
CI+CII(ETS) 0.157 0.003 0.050 
CII(ETS)    0.057 0.001 0.376 
CIV(MAX)   0.718 0.101 0.021 
     
Respiratory 
State 
Flux control ratio (FCR) 
MHN MHS MHN vs MHS 
Control vs halothane-exposure   
(p value) 
Control comparisons (p 
value) 
LEAK    0.753 0.362 0.074 
CI(OXPHOS) 0.480 0.007 0.534 
CI+CII(OXPHOS)  0.470 0.003 0.033 
CI+CII(ETS)       
CII(ETS)     0.041 0.001 0.005 
CIV(MAX)   0.307 0.052 0.913 
     
Respiratory 
State 
FCR Differences (Halothane-exposed - control) 
Kruskal-
Wallis (p 
value)  
Post Hoc (p value) 
MHN vs 
MHSh 
MHN vs 
MHShc 
MHSh vs 
MHShc 
LEAK    0.349       
CI(OXPHOS) 0.209       
CI+CII(OXPHOS)  0.043 1.000 0.036 0.390 
CI+CII(ETS) 0.086       
CII(ETS)      0.263       
CIV(MAX)   0.532       
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hyperthermia susceptible; MHSh = abnormal response in the in vitro contracture test 
to halothane but not caffeine; MHShc = abnormal response in the in vitro contracture 
test to halothane and caffeine.  
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Legends to Figures 
Fig 1. Example high resolution respirometry trace showing the rate of oxygen flux (red 
line) over time after sequential titration of substrates and inhibitors, expressed as 
pmol/s*mg. The blue line represents oxygen levels within the chamber (nmol/ml). 
Vertical dashed lines represent timepoints where substrates have been added. The 
horizontal black lines which overlay the red line plateaus indicate the position of data 
points.  
 
Fig 2. High resolution respirometry of permeabilised Vastus medialis biopsies from 
MHN (n = 36) and MHS (n = 23) individuals. Boxplots show median, IQR and min-
max range for each phenotype in control and halothane-exposed samples. Statistically 
significant pairwise comparisons (p<0.05) are labelled with an asterisk (refer to table 
2 for exact p values). MHN= malignant hyperthermia negative; MHS = malignant 
hyperthermia susceptible. 
 
Fig 3. Boxplot comparison of flux control ratios (FCR) from MHN (n = 36) and MHS 
(n = 23) control and halothane-exposed samples. FCR are generated by internally 
normalizing oxygen flux per muscle mass to the non-halothane-exposed control 
CI+CII(ETS) (indicated by the horizontal dashed line). Boxplots show median, IQR and 
min-max range for each phenotype in control and halothane-exposed samples. 
Statistically significant pairwise comparisons (p<0.05) are labelled with an asterisk 
(refer to table 2 for exact p values). MHN= malignant hyperthermia negative; MHS = 
malignant hyperthermia susceptible. 
 
Fig 4. Boxplot comparison showing the change flux control ratios (FCR) (halothane-
exposed - control) for each respiratory state. MHN samples (n = 36) were plotted with 
MHS samples (n = 23) - further split into MHSh (n = 12) and MHShc (n = 11) subgroups. 
Boxplots show median, IQR and min-max response range for each phenotype. 
Comparisons labelled with an asterisk show statistically significant post hoc pairwise 
comparisons (refer to table 2 for exact p values). MHN= malignant hyperthermia 
negative; MHS = malignant hyperthermia susceptible; MHSh = abnormal response in 
22 
 
the in vitro contracture test to halothane but not caffeine; MHShc = abnormal response 
in the in vitro contracture test to halothane and caffeine 
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Supplementary Table 1 
Patient 
number 
IVCT 
classification 
Contracture at 2% 
halothane (g) 
Contracture at 2 mM 
caffeine (g) 
1 MHSh 0.6 0 
2 MHSh 0.4 0 
3 MHSh 1.05 0 
4 MHSh 0.3 0 
5 MHSh 0.35 0 
6 MHSh 0.2 0 
7 MHSh 0.2 0 
8 MHSh 0.3 0 
9 MHSh 0.2 0.05 
10 MHSh 0.3 0 
11 MHSh 0.2 0.1 
12 MHSh 0.2 0.1 
13 MHShc 0.7 0.2 
14 MHShc 0.7 2.0 
15 MHShc 1.8 1 
16 MHShc 1.05 0.5 
17 MHShc 0.9 0.2 
18 MHShc 1.05 0.75 
19 MHShc 2.55 0.9 
20 MHShc 0.4 0.25 
21 MHShc 1.6 0.4 
22 MHShc 0.9 0.2 
23 MHShc 0.45 0.3 
 
In vitro contracture test (IVCT) responses at 2% halothane and 2 mM caffeine for the 
malignant hyperthermia susceptible patients.  The malignant hyperthermia negative 
patients all had 0 g responses at 2% halothane and 2 mM caffeine. MHSh = abnormal 
response in the in vitro contracture test to halothane but not caffeine; MHShc = 
abnormal response in the in vitro contracture test to halothane and caffeine. 
